Botanix Pharmaceuticals Limited (BXPHF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Botanix Pharmaceuticals Limited (BXPHF) Healthcare & Pipeline Overview

Botanix Pharmaceuticals Limited, based in Australia, specializes in developing novel dermatology and antimicrobial treatments, with a pipeline including Phase 3-ready Sofpironium Bromide for hyperhidrosis and other candidates targeting acne, rosacea, and bacterial infections, positioning them in the competitive biotechnology sector.

What Is the Investment Thesis for BXPHF?

Botanix Pharmaceuticals presents a focused investment opportunity within the dermatology and antimicrobial space. The company's lead product candidate, Sofpironium Bromide, which has completed Phase 3 trials for hyperhidrosis, represents a near-term value driver, contingent on regulatory approval and subsequent commercialization. Further value lies in the advancement of other pipeline assets, including BTX 1503 for acne and BTX 1702 for rosacea, both in Phase IIb trials. However, the company's negative profit margin of -404.7% and gross margin of -118.2% highlight the risks associated with biotechnology companies that are pre-revenue or heavily investing in R&D. Successful navigation of regulatory pathways and strategic partnerships will be crucial for realizing the potential value of Botanix's pipeline. The company's market capitalization is approximately $0.09 billion as of 2026-03-17.

Based on FMP financials and quantitative analysis

BXPHF Key Highlights

• Sofpironium Bromide has completed Phase 3 clinical programs for the treatment of primary axillary hyperhidrosis.
• BTX 1503, a transdermal gel formulation for acne, has completed Phase II clinical trials.
• BTX 1801 has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus.
• BTX 1702 is in Phase IIb clinical trials for the treatment of papulopustular rosacea.
• The company's market capitalization is $0.09 billion as of 2026-03-17.

Who Are BXPHF's Competitors?

BXPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BXPHF's Key Strengths?

• Pipeline of dermatology and antimicrobial products.
• Sofpironium Bromide has completed Phase 3 trials.
• Experienced management team.
• Focus on unmet medical needs.

What Are BXPHF's Weaknesses?

• Negative profit margin.
• Reliance on successful clinical trial outcomes.
• Limited commercialization experience.
• Dependence on regulatory approvals.

What Could Drive BXPHF Stock Higher?

• Potential regulatory approval of Sofpironium Bromide for hyperhidrosis.
• Results from ongoing clinical trials for BTX 1503, BTX 1702, and BTX 1801.
• Advancement of the product pipeline through clinical development stages.
• Strategic partnerships for commercialization and distribution.
• Expansion of the product pipeline to include treatments for other dermatological conditions.

What Are the Key Risks for BXPHF?

• Financial-distress signal — its Altman Z-Score of -5.91 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unsuccessful clinical trial outcomes for drug candidates.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from other pharmaceutical companies.
• Dependence on successful commercialization of approved products.
• Negative profit margin and reliance on funding for R&D.

What Are the Growth Opportunities for BXPHF?

• Growth opportunity 1: Successful commercialization of Sofpironium Bromide for hyperhidrosis represents a significant growth opportunity. The global hyperhidrosis treatment market is expected to reach $1.5 billion by 2030. Upon regulatory approval, Botanix can capture a share of this market through effective marketing and distribution strategies. The timeline for this growth is dependent on regulatory approval, which is anticipated within the next 12-18 months.
• Growth opportunity 2: Expansion of the acne treatment pipeline with BTX 1503 offers another avenue for growth. The global acne treatment market is projected to reach $13.2 billion by 2033. Positive Phase III trial results and subsequent regulatory approval could position BTX 1503 as a competitive product in this market. This growth is anticipated within the next 2-3 years, contingent on successful trial outcomes.
• Growth opportunity 3: Development of BTX 1702 for rosacea provides an opportunity to address a growing market segment. The global rosacea treatment market is expected to reach $2.6 billion by 2033. Successful completion of Phase IIb trials and subsequent advancement through the regulatory process could lead to commercialization within the next 3-4 years.
• Growth opportunity 4: Exploring strategic partnerships for commercialization and distribution can accelerate market penetration. Collaborating with established pharmaceutical companies can provide access to existing distribution networks and marketing expertise, reducing the time and cost associated with launching new products. These partnerships could be established within the next 12 months.
• Growth opportunity 5: Expanding the pipeline to include treatments for other dermatological conditions can diversify the company's revenue streams and reduce reliance on individual products. Identifying and developing new drug candidates for conditions with unmet medical needs can create long-term growth opportunities. This expansion could begin within the next 2 years, focusing on areas with high market potential.

What Opportunities Does BXPHF Have?

• Commercialization of Sofpironium Bromide.
• Expansion of the product pipeline.
• Strategic partnerships with pharmaceutical companies.
• Growth in the dermatology and antimicrobial markets.

What Threats Does BXPHF Face?

• Competition from other pharmaceutical companies.
• Unsuccessful clinical trial outcomes.
• Regulatory hurdles.
• Patent expirations.

What Are BXPHF's Competitive Advantages?

• Proprietary drug formulations.
• Patent protection for novel treatments.
• Clinical trial data supporting efficacy and safety.
• Expertise in dermatology and antimicrobial drug development.

What Does BXPHF Do?

Botanix Pharmaceuticals Limited, incorporated in 1984 and headquartered in Leederville, Australia, is a biotechnology company dedicated to the research and development of innovative dermatology and antimicrobial solutions. The company focuses on addressing common skin diseases and infections through the development of novel treatments. Botanix's product pipeline features several promising candidates, including Sofpironium Bromide, a drug for primary axillary hyperhidrosis that has completed Phase 3 clinical programs. Additionally, BTX 1503, a transdermal gel formulation, is in development for the treatment of serious acne in adults and teenagers, having completed Phase II clinical trials. BTX 1801 has completed Phase IIb clinical trials for treating staphylococcus aureus and methicillin-resistant staphylococcus aureus. BTX 1702 is in Phase IIb clinical trials for papulopustular rosacea, and BTX 1204A is being developed for atopic dermatitis. Botanix Pharmaceuticals aims to provide effective and safe treatments for a range of dermatological conditions and infections, addressing unmet needs in the market. Their focus on late-stage clinical programs positions them for potential commercialization in the near future, pending regulatory approvals.

What Products and Services Does BXPHF Offer?

• Researches and develops dermatology products.
• Develops antimicrobial products.
• Creates novel treatments for common skin diseases.
• Develops treatments for skin infections.
• Conducts clinical trials for drug candidates.
• Seeks regulatory approvals for new products.

How Does BXPHF Make Money?

• Develops pharmaceutical products for dermatology and antimicrobial applications.
• Out-licenses or commercializes approved products.
• Generates revenue through product sales and partnerships.

What Industry Does BXPHF Operate In?

Botanix Pharmaceuticals operates within the biotechnology sector, specifically targeting dermatology and antimicrobial markets. The global dermatology market is characterized by increasing demand for treatments addressing skin diseases and infections. Competition includes companies developing similar products, with the success of Botanix contingent on clinical trial outcomes, regulatory approvals, and market adoption. The company's focus on specific dermatological conditions like hyperhidrosis, acne, and rosacea allows it to target niche markets within the broader dermatology landscape. The biotechnology industry is characterized by high R&D costs and regulatory hurdles, making strategic partnerships and efficient clinical trial management crucial for success.

Who Are BXPHF's Key Customers?

• Patients with skin diseases and infections.
• Dermatologists and other healthcare professionals.
• Pharmaceutical companies through partnerships and licensing agreements.

FY2026 estForward Outlook

Wall Street analysts project Botanix Pharmaceuticals Limited revenue of about $34.8M for fiscal 2026, with EPS near $-0.02. The estimate reflects 3 contributing analysts.

F-Score 3/9Financial Health

Botanix Pharmaceuticals Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.91 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -90.0%, showing how much profit it generates from its asset base. A current ratio of 2.56 indicates the company holds enough short-term assets to cover its near-term obligations.

Botanix Pharmaceuticals Limited (BXPHF) Valuation Context

Valued at $25.9M, BXPHF is classified as a micro-cap stock. Relative to its peer group, BXPHF's quantitative score of 52/100 is roughly in line with the peer average of 46/100.

Company Profile

Botanix Pharmaceuticals Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in West Perth, AU. The company is led by CEO Howie McKibbon. BXPHF has traded publicly since 2019.

BXPHF Financials

BXPHF Latest News

BXPHF Analyst Consensus

BXPHF MoonshotScore

Common Questions About BXPHF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources